准Cdc2类激酶2以克服卵巢癌中白金耐药性的卵巢癌
Yinan Jiang1, Shuting Huang2, Lan Zhang3
1Department of Gynecology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou China.
MedComm
|April 15, 2024
概括
类似Cdc2的激酶2 (CLK2) 通过增强DNA修复,促进卵巢癌 (OC) 中的抗性. 向CLK2提供了一种潜在的策略来克服耐药性,特别是在野生型BRCA1.1患者中.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 抗性是卵巢癌 (OC) 治疗中的一个重大挑战.
- 在OC进展和抗性中,Cdc2样酶2 (CLK2) 的作用尚不清楚.
研究的目的:
- 研究CLK2在卵巢癌进展和抗性中的作用和机制.
- 探索CLK2作为一种潜在的治疗标来克服OC中的抗性.
主要方法:
- 微阵列基因表达分析和OC组织的免疫染色.
- 在OC细胞的体外功能测定和使用瘤异种移植的体内研究.
- 通过p38对CLK2酸化的分析及其对乳腺癌基因1 (BRCA1) 的影响.
主要成果:
- 在OC组织中,CLK2被上调,并且与较短的无间隔相关.
- 在异种移植中,CLK2过度表达赋予了对诱导的亡的耐药性,并降低了治疗疗效.
- 在Ser1423中,CLK2化BRCA1,增强DNA损伤的修复,并导致抗性.
- 在处理的OC细胞中,p38激酶稳定了CLK2蛋白.
- 与CLK2和多 (ADP-ribose) 聚合酶抑制剂的联合治疗显示出协同作用的致死性,特别是在野生型BRCA1瘤中.
结论:
- 通过增强DNA修复,CLK2在卵巢癌中促进白金耐药性起着至关重要的作用.
- 针对CLK2,与PARP抑制剂结合,为克服OC中的抗性提供了一个有希望的策略,特别是在BRCA1-野生型环境中.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer-Critical Genes II: Tumor Suppressor Genes
7.4K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.4K


